Shatavari and PCOS: The Trial Missed Its Primary Outcome, and the Result Is Still Interesting

Shatavari (Asparagus racemosus) has been used in Ayurvedic practice for women's reproductive health for a very long time, which is the kind of pedigree that makes a modern trial both necessary and interesting to read closely. A new randomized, double-blind, placebo-controlled study tested a standardized shatavari root extract in women with Polycystic Ovary Syndrome (PCOS). The coverage says it showed improvement. The trial's own primary outcome was more complicated.

Photo: 本草圈 / Unsplash

The results, in order of importance

Researchers in India randomized 70 women aged 20 to 40 with PCOS to either standardized shatavari root extract or placebo for twelve weeks, with 66 completing the full protocol [1]. Neither the participants nor the investigators knew who was getting what. Assessments happened at baseline, week 4, week 8, and week 12, with bloodwork at the start and end covering HbA1c, lipids, insulin, reproductive hormones, and liver, kidney, and thyroid function.

The primary outcome was change in ovarian and endometrial measures. Ovarian volume did not differ between the groups (p = 0.254). That is the trial's main question, and the answer was no.

Three secondary findings changed. Perceived stress dropped substantially in the shatavari group, by 6.64 points on the PSS-10 scale, with a p-value below 0.0001. Antral follicle count decreased. Endometrial thickness increased modestly. Safety looked reassuring: no serious adverse events, and mild-to-moderate events in 11.4 percent of the shatavari group against 8.5 percent on placebo.

The measures that did not change are just as important: there was no significant change in BMI, in hormone levels, or in HbA1c, insulin, or lipids.

What the headline leaves out

PCOS is characterized in large part by androgen excess and insulin resistance. With no change in reproductive hormones and no change in insulin or HbA1c over twelve weeks, the trial has not demonstrated an effect on the mechanisms that define the condition. Calling that "improvement in PCOS" claims more than the data show.

The stress finding is the most robust number in the paper and also the one most vulnerable to bias. The PSS-10 is a self-report questionnaire, and a 6.64-point shift is large for a twelve-week herbal intervention. Blinding helps, though participants may guess which group they are in once they notice they feel different. Seventy participants is also a small sample for drawing firm conclusions about anything.

Comparing shatavari with other options helps. A 2026 network meta-analysis compared GLP-1 receptor agonists, metformin, and myo-inositol across sixteen randomized trials [2]. The combination of a GLP-1 agonist plus metformin produced the largest weight and BMI reductions. None of those interventions significantly improved insulin resistance as measured by HOMA-IR, which shows how hard that particular target is to change even with pharmaceutical tools. In a separate meta-analysis of twelve trials, cinnamon supplementation improved fasting glucose, insulin resistance, and cholesterol in women with PCOS [3]. So another botanical has produced metabolic improvements in PCOS that shatavari did not.

Why the type of PCOS changes the question

PCOS comes in more than one form. Clinically it sorts roughly into an insulin-resistant presentation, an adrenal or stress-related presentation, and an inflammatory presentation, with plenty of overlap. Two women can meet the same diagnostic criteria and need almost nothing in common.

Seen that way, a botanical that lowers perceived stress without changing insulin could be a poor match for one type of PCOS and a reasonable one for another. The women in this trial weren't sorted by presentation, so a true benefit in a stress-related subgroup could easily be diluted into nonsignificance across a mixed sample. That is a limit of the study design, and it doesn't settle whether the herb helps.

I would also resist writing off the stress result because it's subjective. The hypothalamic-pituitary-adrenal axis is involved in PCOS, and chronic stress load affects cycles, sleep, appetite, and insulin signaling over time. Beyond mechanism, women with PCOS carry a documented burden of anxiety and distress that goes chronically under-addressed while the conversation stays on labs. When an intervention helps someone feel less overwhelmed, it is doing something useful, even if nothing changes on a metabolic panel.

Should you try shatavari for PCOS?

Treat this as an early, small, and mostly negative trial with one interesting positive signal, seeing as that's what it is. It doesn't establish shatavari as a PCOS treatment, and the endometrial thickness change should not be treated as a fertility outcome. It wasn't studied as one.

If you have PCOS and are curious about botanicals, the more productive question is which version of PCOS you have. Before deciding what to treat first, I would look at fasting insulin, HbA1c, and androgens, and take a frank look at stress and sleep load. You learn more from that than from any single herb's press coverage. Bring shatavari to your provider rather than adding it on your own, since herbs have active pharmacology and can interact with hormonal medications.

References

1. Mhatre Y, Jadhav P, Malik A, Srivathsan M, Langade D. Efficacy and safety of Shatavari root extract in women with Polycystic Ovarian Syndrome: a randomized, double-blind, placebo-controlled trial. Front Endocrinol (Lausanne). 2026;17:1769773. PMID 41816216. DOI 10.3389/fendo.2026.1769773. Trial registration CTRI/2024/10/074660.

2. Omarion A, Ayasa Y, Omarion Z, Jayouse B, Ayesh H. Comparative analysis of glucagon-like peptide-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes in women with polycystic ovary syndrome: a network meta-analysis. Front Endocrinol (Lausanne). 2026;17:1833904. PMID 42490840. DOI 10.3389/fendo.2026.1833904. (A published correction to this article appeared as PMID 42549142.)

3. Xiaomei Z, Xiaoyan F. Effect of cinnamon as a Chinese herbal medicine on markers of cardiovascular risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 2024;300:253–261. PMID 39053085. DOI 10.1016/j.ejogrb.2024.07.032

4. American Botanical Council. Shatavari shows improvement in polycystic ovary syndrome. HerbClip, HerbalGram issue 788, 2026. https://www.herbalgram.org/resources/herbclip/issues/2026/issue-788/shatavari-polycystic-ovary-syndrome/ (secondary review of the primary trial above).

Reference metadata verified against PubMed.

A closing note

This is educational information and not medical advice, and it can't substitute for care from a clinician who knows your history and your labs. PCOS is a real endocrine condition that deserves proper evaluation. If you're managing it, or trying to conceive, or taking hormonal medication of any kind, please talk with your own provider before adding a botanical.

---

If this resonates with what you're experiencing and you'd like to explore a naturopathic approach, book a consultation with our clinic.